Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences Corp. (NASDAQ: EXAS) presented new data at the ACG Annual Meeting showcasing the impact of eliminating patient costs for follow-up colonoscopies. The findings suggest that a cost-free approach could significantly increase colorectal cancer screening rates, with over 900 deaths averted per 1 million people screened. Additionally, Cologuard was highlighted for its effectiveness in detecting serrated polyps, and its role in redefining false positive outcomes in stool tests was discussed. The new evidence reinforces Cologuard as a valuable non-invasive screening option in the fight against colorectal cancer.

Exact Sciences Corp. (Nasdaq: EXAS) announced the release of its third quarter 2022 financial results, scheduled for November 3, 2022, after U.S. market close. Management will discuss the results and business updates during a webcast at 5 p.m. ET the same day. Investors can access the live webcast through the company's website. Exact Sciences focuses on cancer screening and diagnostics, leveraging products like Cologuard^® and Oncotype^®. Further information can be found on their official site.

Exact Sciences (Nasdaq: EXAS) showcased a multi-cancer early detection study at the ESMO Congress, reporting a sensitivity of 61% and a specificity of 98.2%. This study validates a multi-biomarker approach to identify cancer across 15 organ sites, improving early detection, particularly in stages I (31.4%) and II (45.8%). With no recommended screening for 70% of cancers and as cancer remains a leading cause of death, these findings support the future of cancer diagnostics. Exact Sciences will initiate the largest registrational trial, SOAR, in 2023 to further explore these results.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in the Baird Global Healthcare Conference set for September 13, 2022, at 3:45 p.m. ET. Investors can join the fireside chat via webcast on Exact Sciences' investor relations website. The company focuses on innovative cancer screening and diagnostic solutions, enhancing its product pipeline, including Cologuard® and Oncotype® tests, to support patients through their cancer journeys. For more details, visit www.exactsciences.com.

Exact Sciences reported second quarter revenue of $521.6 million, up 20% from $434.8 million in 2021. Excluding COVID-19 testing, revenue rose 26%, driven by a 34% increase in Screening revenue to $353.9 million, and a 12% increase in Precision Oncology revenue to $154 million. Despite this growth, the company recorded a net loss of $166.1 million, or $0.94 per share. The updated 2022 revenue outlook is between $1,980-$2,022 million, reflecting adjustments in Precision Oncology projections.

Exact Sciences Corp. (NASDAQ: EXAS) announced a collaboration with the West German Study Group (WSG) to conduct a multicenter validation study on minimal residual disease (MRD) in hormone receptor-positive, HER2-negative early breast cancer patients. The ADAPT Triad study aims to utilize Exact Sciences' ctDNA liquid biopsy test for detecting MRD, involving data from about 3,000 patients. This initiative supports Exact Sciences' goal to develop clinically validated MRD tests, enhancing treatment decisions and patient outcomes.

Exact Sciences Corp. (EXAS) announced its upcoming participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10, 2022, at 4:00 p.m. ET. The event will include a fireside chat, inviting investors to join via webcast. Exact Sciences, recognized for its innovative cancer screening and diagnostic tests, continues to seek advanced solutions for early cancer detection and treatment. The webcast will be accessible through their investor relations section at www.exactsciences.com.

Exact Sciences Corp. (NASDAQ: EXAS) applauds the CMS proposal to classify follow-up colonoscopy after positive at-home colorectal cancer tests as a preventive service, eliminating costs for Medicare patients. The proposal extends coverage to individuals aged 45 and older and aligns with recommendations from the USPSTF and the American Cancer Society. With 44 million unscreened average-risk adults in the U.S., this change aims to increase access to cancer screening and early detection. The final rule is expected to be published in fall 2022 and take effect on January 1, 2023.

Exact Sciences Corp. (Nasdaq: EXAS) announced it will release its second quarter 2022 financial results after the U.S. markets close on August 2, 2022. Following the announcement, management will host a webcast and conference call at 5 p.m. ET to discuss the results and business progress. The call is accessible via telephone and will also be available as a recorded archive on their website. Exact Sciences focuses on cancer screening and diagnostic tests, notably with products like Cologuard and Oncotype.